fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Alendronate

All products: general benefit

Mint-Alendronate · DIN 02394863 · 10 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.Discontinued August 1, 2018 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Mint-Alendronate · DIN 02394863 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-03-20 Health Canada: Cancelled post market since 2018-08-01 · brand MINT-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10.0 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Alendronate: Formulary list price $0.50 per unit (the source does not state the unit; exact figure $0.4987). What the ministry pays, not the patient.

Ministry pays: $0.4987 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394863)

Source record
DIN 02394863: Mint-Alendronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000232; group id 891; item number 2141; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4987; ministry $0.4987 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394863 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88002
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987 Apo-Alendronate · DIN 02248728 · $0.4987 Auro-Alendronate · DIN 02388545 · $0.4987 Fosamax · DIN 02201011 · not recorded Ran-Alendronate · DIN 02384701 · $0.4987 Sandoz Alendronate · DIN 02288087 · $0.4987 Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since August 1, 2018 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable

  • Risedronate (Actonel DR): general benefit, not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
  • Etidronate (Didronel): limited Use 236, 237, not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FOSAMAX® (alendronate sodium) is indicated for: • The treatment of osteoporosis in postmenopausal women. o For the treatment of osteoporosis in postmenopausal women, FOSAMAX® increases bone mass and prevents fractures, including those of the hip and spine (vertebral compression fractures). • The treatment of osteoporosis in men. o For the treatment of osteoporosis in men, FOSAMAX® increases bone mass and reduces the incidence of fractures. • The prevention of osteoporosis in postmenopausal women1 o For the prevention of osteoporosis, alendronate sodium may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. • The treatment and prevention of glucocorticoid-induced osteoporosis in men and women.1 o Alendronate sodium is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. 1 Although alendronate tablets 5 mg, 10 mg, a… https://pdf.hres.ca/dpd_pm/00071922.PDF PM date: not printed or not captured Source product: FOSAMAX; DIN 02245329; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.